Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05454280 · ClinicalTrials.gov registry record · Phase 3

Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)

A Phase 3 study of Cancer and Surgery, sponsored by Fox Chase Cancer Center.

Recruiting
Registry status
Phase 3
Development phase
880
Enrollment target
1
Study location

NCT05454280 is a Phase 3 study of Cancer and Surgery that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 880 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05454280, a Phase 3 study of Cancer and Surgery, is actively recruiting participants, sponsored by Fox Chase Cancer Center.

RECRUITING
Registry status
Phase 3
Development phase
880 participants
Enrollment target
1
Study location

Study Summary

This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).

Conditions Studied

Interventions

  • PROCEDURE Intensified post-discharge surveillance
  • PROCEDURE Standard post-discharge surveillance

Study Locations (1)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 880 participants
Start Date 2022-10-14
Est. Completion 2028-11-01
Phase Phase 3

Sponsor

Fox Chase Cancer Center

183 total trials

What the Registry Record Tells You About NCT05454280

The ClinicalTrials.gov registry entry for NCT05454280 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Intensified post-discharge surveillance is the first listed.

NCT05454280 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05454280 about?

NCT05454280 is a clinical study titled "Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)". This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).

What is the current status of trial NCT05454280?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2022-10-14. Estimated completion is 2028-11-01.

What conditions does trial NCT05454280 study?

This clinical trial studies the following conditions: Cancer, Surgery.

What interventions are being tested in trial NCT05454280?

The interventions under investigation include: Intensified post-discharge surveillance (PROCEDURE), Standard post-discharge surveillance (PROCEDURE).

Who is sponsoring clinical trial NCT05454280?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05454280 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.